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Abstract
Background—In recent influenza seasons, the live attenuated influenza vaccine (LAIV) has not 
demonstrated the same level of vaccine effectiveness as that observed among children who 
received the inactivated influenza vaccine (IIV). To better understand this difference, this study 
compared the mRNA sequencing transcription profile (RNA seq) in children who received either 
IIV or LAIV.
Methods—Children 3–17 years of age receiving quadrivalent influenza vaccine were enrolled. 
Blood samples were collected on Day 0 prior to vaccination and again on Day 7 (range 6–10 days) 
following vaccination. Total RNA was isolated from PAXgene tubes and sequenced for a custom 
panel of 89 transcripts using the TruSeq Targeted RNA Expression method. Fold differences in 
normalized RNA seq counts from Day 0 to Day 7 were calculated, log2 transformed and compared 
between the two vaccine groups.
Results—Of 72 children, 46 received IIV and 26 received LAIV. Following IIV vaccination, 7 
genes demonstrated significant differential expression at Day 7 (down-regulated). In contrast, 
following LAIV vaccination, 8 genes demonstrated significant differential expression at Day 7 (5 
up-regulated and 3 down-regulated). Only two genes demonstrated similar patterns of regulation in 
both groups.
Correspondence: Richard K. Zimmerman, MD, MPH, University of Pittsburgh, Department of Family Medicine, Suite 520 Schenley 
Place, 4420 Bayard Street, Pittsburgh PA 15260, zimmer@pitt.edu, 412/383-2354. 
Clinical Trial Registry: N/A
Potential Conflict of Interest: Drs. Zimmerman has research funding from Sanofi Pasteur, Inc. Pfizer, Inc. and Merck & Co., Inc. Dr. 
Lin has research funding from Sanofi Pasteur, Inc. and Merck & Co, Inc. Dr. Nowalk has research funding from Pfizer, Inc. and Merck 
& Co., Inc. Dr. Alcorn has research funding from MedImmune, LLC and Merck & Co.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Vaccine. Author manuscript; available in PMC 2018 December 14.
Published in final edited form as:
Vaccine. 2017 December 14; 35(49 Pt B): 6893–6897. doi:10.1016/j.vaccine.2017.09.019.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Conclusions—Differential regulation of genes was observed between 2015–16 LAIV and IIV 
recipients. These results help to elucidate the immune response to influenza vaccines and may be 
related to the difference in vaccine effectiveness observed in recent years between LAIV and IIV.
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INTRODUCTION
In recent influenza seasons, the live attenuated influenza vaccine (LAIV) has offered limited 
protection from influenza to children in the United States (U.S.). Specifically, the vaccine 
effectiveness (VE) of LAIV against any influenza in children 2–17 years old was 7% 
(95%CI = −46 to 40%) in 2013–2014 [1] and 26% (95%CI = 3 to 44) in 2014–2015 [2]. 
LAIV’s VE against influenza A/H3N2 was especially low among children 2–17 years in 
2014–2015 (−6% VE; 95%CI = −40% to 20%), while LAIV offered reasonable protection 
(74% VE (95%CI= 25% to 91%)) against the less commonly occurring influenza B [2]. In 
the prior (2013–2014) season, VE of LAIV against (A/H1N1) was poor [1], but influenza A/
H1N1 did not circulate widely in 2014–15, thus VE was not calculated. The reason for the 
reported decline in LAIV VE from previous seasons [3, 4] is unclear. Initially believed to be 
due to heat instability of the A/H1N1 construct in 2014–2015 [5, 6], manufacturer’s 
modifications of the vaccine did not improve VE in 2015–2016 season [7]. In response to 
this low VE, the Advisory Committee on Immunization Practices does not currently support 
the use of LAIV, thereby removing the intranasal delivery mechanism preferred by many 
children. Studies are needed to help to determine what accounts for the differences in VE 
between LAIV and inactivated influenza vaccine (IIV).
In a previous study of children ages 3 to 17 years, post 2014–2015 influenza vaccination 
antibody titers were significantly higher in response to IIV than to LAIV [8]. Moreover, 
microneutralization antibodies measuring cross-reactive protection against influenza were 
significantly higher among recipients of IIV than LAIV. It is likely that other immune 
responses, including cellular or mucosal immune responses, differ between LAIV and IIV 
recipients.
RNA sequencing is a technique that has been used to examine the cellular transcriptome 
such as gene expression, and provides a snapshot at the time of blood collection. Changes in 
the transcriptome before and after vaccination may identify transcription profiles and 
pathways of response that can be used for future vaccine development.
This study was designed to compare the RNA seq responses to the 2015–2016 IIV versus 
LAIV in children during the last year when LAIV use was recommended in the U.S. 
Specifically, selected gene profiles known to be related to viral infection, as well as the 
innate and adaptive immune responses to influenza, were compared.
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METHODS
This study was approved by the University of Pittsburgh Institutional Review Board. Written 
informed consent was obtained from the participants’ parents.
Subjects, Eligibility and Enrollment
This study was conducted before influenza was circulating in the region [9]. From 
September through December 2015, a convenience sample of healthy children aged 3 
through 17 years who planned to receive influenza vaccine were recruited from 3 primary 
care offices in the Pittsburgh area. Exclusion criteria included body weight <17 kilograms, 
having an immunosuppressive disease, taking immunosuppressive medicine or high dose 
oral steroids, pregnancy, and having a severe allergy to the influenza vaccine or its 
components. Parents could choose which form of the quadrivalent vaccine they preferred 
and the children were grouped by the vaccine received. All children received quadrivalent 
vaccines: IIV was either Fluzone (Sanofi Pasteur) or Fluarix (GlaxoSmithKline) as 
determined by their health insurance. Quadrivalent LAIV was FluMist (MedImmune). 
Demographic data were provided by the families and/or extracted from the electronic 
medical record.
Specimen Collection and Processing
On Day 0, participants provided blood samples prior to receiving influenza vaccine as part 
of their clinical care; they returned on Day 7 (range 6–10 days) for an additional blood draw. 
Within 4–6 hours of collection, blood samples collected into PAXgene tubes (Becton 
Dickinson) were centrifuged at 3200 rpm for 10–15 minutes and stored at −70°Celcius until 
further analysis.
RNA sequencing
Total RNA was isolated from PAXgene tubes using the PAXgene Blood RNA Kit following 
the manufacturer’s protocol. The 89 transcripts selected for testing were based on the 
knowledge of the investigators and local experts of genes known to have a role in influenza 
and other viral infections and a review of the medical literature for prior similar studies (See 
Supplemental Tables for a list of all transcripts). Both LAIV and IIV recipients were tested 
for all 89 transcripts. RNA quality and quantity were assessed by Agilent Tapestation 2200 
and Invitrogen Qubit 2.0 fluorometer. Using 50 ng of total RNA, a multiplexed gene 
expression profiling panel of the selected targets was performed using the TruSeq Targeted 
RNA Expression Reference Guide, Rev. C[10]. Single-read 50 base pairs (bp) sequencing 
was performed on an Illumina NextSeq 500 with an average of 2 million reads per sample. 
Sequencing libraries were normalized to 2nM and then pooled.
Alignment
The banded Smith-Waterman algorithm was used to align clusters from each sample against 
the amplicon sequences provided in the kits to determine similar regions between 2 
sequences, comparing segments of all possible lengths. If the start of a read matched a probe 
sequence with no more than 1 mismatch, the full length of the read was aligned against the 
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amplicon target for that sequence. Alignments that included more than 3 indels (insertions or 
deletions) were excluded from alignment results.
Statistical Analyses
Depth of sequencing, variance estimation and calculation of p and q values—
Depth of sequencing was used to compare samples for differences between Day 0 and Day 
7. For each RNA transcript, the raw counts and the geometric mean of aligned read counts 
were calculated for all samples. A scaling factor (median of the ratio of raw counts to the 
geometric mean) was then used to normalize raw counts, dividing raw counts by the scaling 
factor to enable comparison of non-differentially expressed transcripts. The bias inherent in 
estimating variance is correlated with the number of biological replicates; thus, variance was 
calculated using data from all sample IDs rather than calculating for each sample name 
separately. The squared coefficient of variation was calculated by dividing the raw variance 
by the square of the mean.
Fold differences in normalized RNA seq counts from Day 0 to Day 7 were calculated and 
log2 transformed. A negative binomial distribution was used to model the normalized 
transcript abundance to derive a P-value for the differential expression (up- or down-
regulations) of each transcript. Q-values were computed using the Benjamini-Hochberg 
procedure to control the false discovery rate by correcting for multiple hypothesis testing.
Patient characteristics—Demographic characteristics of recipients, including age groups 
(3–8 years vs. 9–17 years), sex, race (Black vs. non-Black), health insurance (public vs. 
private insurance), parent’s educational level (high school or less vs. some college or higher 
degree), and household smoking status, were compared by vaccine type (LAIV vs. IIV) 
using Chi-square or Fisher’s exact tests. Statistical significance was set at P < 0.05.
RESULTS
Seventy-two participants provided adequate Day 0 and Day 7 blood samples for analysis. 
The demographic characteristics of IIV recipients did not differ from LAIV recipients (Table 
1). Differentially expressed genes (DEGs) with a p-value < 0.05 were identified and are 
shown in Table 2. Following IIV vaccination, 7 genes demonstrated significant differential 
expression at Day 7, all down-regulated; whereas, LAIV vaccination resulted in a total of 8 
genes with significant differential expression at Day 7, with 5 up-regulated and 3 down-
regulated. Two genes with significant differential expression at Day 7 were common to both 
vaccine types, both were down-regulated (CCL 7 and CXCR4). Most interesting was the 
striking difference between the two vaccines, where IIV vaccination resulted in down-
regulated 7 genes compared to LAIV vaccination which resulted primarily in up-regulation 
of 5 different genes. Figure 1, a heat map of the gene expression, shows the differences 
between RNA seq responses to the two vaccine types.
Discussion
Systems biology approaches have been used in influenza research since 2011. The present 
study was designed to analyze RNA transcripts following IIV compared to LAIV 
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vaccination during a year when the influenza vaccine was well-matched to the circulating 
strains. Our results demonstrated a remarkable difference between the two vaccines, where 
most of the genes expressed following IIV vaccination were down-regulated, while genes 
expressed after LAIV vaccination were predominantly upregulated. We found differences in 
transcriptional changes when comparing IIV with LAIV for the 2015-16 season; others have 
found differences in a previous season's vaccines [11]. The expression of two genes, CCL7 
and CXCR4, demonstrated similar changes in magnitude and direction in both IIV and 
LAIV recipients.
The genes with significant differential expression in response to IIV included the T cell 
related cytokine interleukin (IL)4, which is a B cell stimulating cytokine produced by 
activated Type 2 T-helper cells (Th2) and IL12B (IL12p40) a cytokine subunit of IL12 and 
IL23, which prime Th1 and Th17 responses, respectively. This finding suggests decreased T 
cell activation 7 days post-vaccination. Interferon alpha 1 (IFN A1), a canonical antiviral 
gene was also downregulated by vaccination. Finally, monocyte and neutrophil chemokines 
and receptors were decreased, including CCL2 (MCP-1), CCL7 (MCP-3), and CXCR4 
(SDF1 receptor), which mediate monocyte chemotaxis, and IL8, a prominent neutrophil 
chemoattractant. These data suggest an anti-inflammatory state 7 days post-vaccination.
Unlike the PBMC response to IIV, we found five upregulated DEGs following LAIV that 
indicates an interferon stimulated gene (ISG) response. This ISG response to LAIV was 
distinct from that observed with IIV. Among these five genes, two are involved in inducing 
or regulating apoptosis of infected or abnormal cells: Interferon alpha Inducible Protein 6 
(IFI6) and Tumor Necrosis Factor Superfamily member 10 (TFNSF10/TRAIL). Another two 
upregulated DEGs, Myxovirus Dynamin Like GTPase 1 (MX1) and Interferon Induced 
Protein with Tetratricopeptide Repeats 3 (IFIT3), are known inhibitors of influenza virus 
replication and promote interferon signaling. Finally, C-X-C Motif Chemokine Ligand 10 
(CXCL10/IP-10) is a type II interferon induced gene that promotes lymphocyte chemotaxis. 
These upregulated DEGs are largely involved in the canonical interferon signaling pathway 
that is invoked in response to live virus infection. Why LAIV induces interferon signaling, 
while IIV did not at this time point, is unknown, but intriguing. The association of LAIV 
vaccination with upregulation of genes involved in apoptosis may be indications of alternate 
mechanisms of action [12], and warrant further evaluation of immune responses associated 
with LAIV vaccination.
The dramatic difference between transcriptomic responses to the two vaccines and previous 
findings that children who received LAIV generated a less robust IgG antibody response 
than those who received IIV [8] provide new insights to help explain the lower vaccine 
effectiveness of LAIV observed during the 2015–16 influenza season [7]. Cao et al., found 
differential expression in the IIV group of plasma cell-mediated and inflammation genes, but 
in the LAIV group found IFN and cell-cycle-related transcripts [11]. IIV has been found to 
induce expression of IFN genes at day 1 post vaccination, while LAIV was not found to be 
associated with these changes until day 7 [10]. It is possible that IIV induced gene 
expression occurs earlier than LAIV and this temporal difference in transcriptional 
regulation may affect protective immunity. The pattern of overexpression of IFN genes has 
been suggested as a biomarker of vaccination response [13]. Certain IFN-related DEGs were 
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also correlated with antibody response. We add to this important work of Cao et al., by 
including a larger sample size of children using data from the last season that LAIV was 
widely used and a season when LAIV did not perform well, as reported by the US Flu VE 
Network [7].
Identification of predictive signatures of serologic response to vaccination is an emerging 
field of systems biology. Bucasas et al. were among the first to demonstrate a positive 
correlation between HA titers and upregulation of interferon-responsive genes early after IIV 
vaccination [14]. Elevated antibody titers to IIV are correlated with upregulation of B-cell 
specific transcripts, upregulation of immunoglobulin genes, and proliferation-associated 
genes. These responses may be predictors of vaccine-specific antibody and plasmablast 
responses at seven days post vaccination [15], as Kim et al. have shown a similar 
relationship between antibody titers and circulating plasmablasts following IIV vaccination 
[16]. More recently, a methodology has been described for isolating and characterizing RNA 
transcripts in peripheral blood cell subsets compared to whole blood following influenza 
vaccination [17].
This approach, combining systems biology and predictive modeling to vaccinology, provides 
a powerful tool for unraveling the molecular mechanisms of vaccine-induced immunity [18, 
19]. Systems vaccinology has recently been used to successfully study the immune 
responses to influenza vaccination in adults [14, 17, 19–23]. The current study adds to the 
body of systems vaccinology literature for understanding immune response to influenza 
vaccine among children and highlights the many differences between responses to LAIV and 
IIV. It is important to note that these differences may not reflect potential differences in 
response to infection with wild type influenza compared with LAIV [13, 24].
Strengths and Limitations
The primary strength of this study is that it uses one of few data sets available on the 
transcriptional response to the 2015–2016 influenza vaccine when LAIV had limited 
effectiveness but was still widely being used. Further, many of the children sampled had 
been enrolled in the study for two or more years, providing a unique opportunity to evaluate 
and compare immunity elicited by LAIV to that of IIV and the impact of prior vaccination. 
Investigators at Stanford confirmed limitations of using current serum antibody assays to 
monitor vaccine effectiveness, demonstrating that prior vaccination priming was critical for 
the effective immune response to the current vaccine year as measured by plasmablast and 
other more in-depth immune responses [25]. Of note, a larger proportion of children 
received IIV compared to LAIV, as this was a convenience sample of children for whom 
sufficient specimen volume for both Day 0 and Day 7 were available. A limited set of pre-
selected genes was used for testing; however, this selection was based on the knowledge of 
local experts and review of the medical literature of prior similar studies. It is possible that a 
larger sample size or examination of other genes would generate additional results and that 
another mechanism explains the differences in response. Given the limitations in sample 
size, we report both P and Q values in Table 2, thereby allowing readers to determine which 
they prefer. Furthermore, these findings should be evaluated in the context of a broad 
spectrum of humoral antibody responses (IgG and IgA), protein expression and cell 
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mediated responses in the same population. It has recently been suggested that obesity and 
exposure to cigarette smoke may each be associated with immune dysfunction and may 
affect response to vaccines [26, 27]. However, Smit et al. did not demonstrate a difference in 
rates of PCR confirmed influenza in vaccinated obese children compared with vaccinated 
non-obese children [28]. The current study was not large enough to examine these variables 
and future studies should further evaluate these relationships. Additional factors that may 
affect VE, which we could not evaluate in our study, include vaccine match and mutations 
due to passage of the vaccine virus in eggs during manufacturing [29].
Conclusion
Differential gene expressions were observed between children who received the 2015–16 
IIV and those who received the LAIV. These transcriptional profiles help to elucidate the 
differences in the immune response to influenza vaccines and may help to explain why 
LAIV has not been as effective as IIV in recent years.
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Key points – Vaccine RNA seq paper
Selected RNA sequencing was studied before and after LAIV and IIV 
administration in children.
After IIV vaccination, 7 genes demonstrated significant differential expression at 
Day 7 (down-regulated).
In contrast, following LAIV vaccination, 8 genes demonstrated significant 
differential expression at Day 7 (5 up-regulated and 3 down-regulated).
Only two genes demonstrated similar patterns of regulation in both groups (down-
regulated).
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Figure 1. Heat maps of RNA-seq responses to IIV and LAIV
Heat maps representing differential expression of genes between Day 0 (pre) and Day 7 
(post) vaccination based on P<0.05. IIV = inactivated influenza vaccine; LAIV = live 
attenuated influenza vaccine
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Table 1
Demographic Characteristics of Participants Overall and by 2015–2016 Influenza Vaccine Type
Variable
Total
N=72
n (%)
LAIV*
N=26
n (%)
IIV**
N=46
n (%)
P-value†
Age 9–17 years, ref. = 3–8 years 58 (80.6) 20 (76.9) 38 (82.6) 0.558
Male, ref. = female 31 (43.1) 9 (34.6) 22 (47.8) 0.277
Black race, ref. = white and others 62 (86.1) 22 (84.6) 40 (87.0) 0.783
Parent’s education ≥ some college, ref. = high school or less 40 (55.6) 16 (61.5) 24 (52.2) 0.442
Public health insurance, ref. = private insurance 64 (88.9) 24 (92.3) 40 (87.0) 0.488
Smoker in household 31 (43.1) 8 (30.8) 23 (50.0) 0.113
*
Live attenuated influenza vaccine
**
Inactivated influenza vaccine
†
By Chi-square test
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